Previous 10 | Next 10 |
Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes PR Newswire R289 is an investigational, oral, inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), being studied as a potentially differentiated app...
5 Penny Stocks To Watch In December With High Marks From Analysts Trading penny stocks has the potential to be a very profitable technique. However, due to the volatility, these trades are seen as having a more significant risk than other types of investments. For individuals seeking to build...
Penny Stocks Under $1 The basic definition of penny stocks includes those trading below $5. But if you ask most retail traders, they think of penny stocks as stocks trading for pennies a share. That means the vast majority are hunting for stocks under $1, and 2022 has been a year in which...
3 Tips for Investing in Penny Stocks Right Now Investing in penny stocks is an attractive option for those looking to build their portfolio with a decent level of risk and potentially high returns. Penny stocks , or small-cap stocks priced at less than $5 per share, are often overlooked b...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Moab Republic / Shutterstock.com Bath & Body Works (NYSE: BBWI ) stock is rising higher on Friday as the retail company starts its annual Candle Day sale . Members of Bath & Body Works’ loy...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Rigel Pharmaceuticals (NASDAQ: RIGL ) stock is heading higher on Friday after getting approval from the U.S. Food and Drug Administration (FDA) for its leukemia treatment. Specifically, the ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re starting off the day with an overview of the biggest pre-market stock movers for Friday! Moving stocks are earnings reports, clinical trial data, and more. Let’...
Rigel Announces U.S. FDA Approval of REZLIDHIA™ (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation PR Newswire REZLIDHIA is a potentially market-leading, oral, mutant isocitrat...
Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology PR Newswire Early clinical data support olutasidenib's potential as a treatment for AML and MDS, in both the relapsed/refractory and newly diagnosed settings Olutasid...
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2022 Earnings Conference Call November 3, 2022 4:30 AM ET Company Participants Dolly Vance - Senior Advisor, Legal & Corporate Affairs Raul Rodriguez - President and CEO Wolfgang Dummer - Executive Vice President and Chie...
News, Short Squeeze, Breakout and More Instantly...
Rigel Pharmaceuticals Inc. Company Name:
RIGL Stock Symbol:
NASDAQ Market:
Rigel Pharmaceuticals Inc. Website:
2024-06-27 09:02:05 ET Rigel Pharmaceuticals (RIGL) announced stock split at a ratio of 1-for-10 on 2024-06-27 ... Full story available on KlickAnalytics.com
Rigel Announces Reverse Stock Split PR Newswire SOUTH SAN FRANCISCO, Calif. , June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common st...
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application PR Newswire GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- Rigel Pharmac...